GO:0014891 striated muscle atrophy: Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0014891 (striated muscle atrophy) is a biological process defined as a decrease in protein content, fiber diameter, force production and fatigue resistance in striated muscle in response to conditions such as starvation, aging and disuse.
• The process affects both skeletal and cardiac striated muscle and is driven by an imbalance between protein degradation and protein synthesis, with the ubiquitin-proteasome system playing a central role.
• The E3 ubiquitin ligases MuRF1 (TRIM63) and MAFbx/atrogin-1 (FBXO32) are established markers and effectors of skeletal muscle atrophy and are transcriptionally induced in multiple atrophy models.
• Disuse, immobilisation, denervation, aging, metabolic disease and obesity are major triggers of striated muscle atrophy, each engaging overlapping but distinct molecular programs.
• Mitochondrial dysfunction, altered mitochondrial dynamics and mitophagy are increasingly recognized as integral mechanisms contributing to muscle atrophy.
• Understanding GO:0014891 supports research into sarcopenia, cachexia, disuse atrophy and metabolic myopathies, and informs therapeutic strategies targeting protein turnover and mitochondrial quality control.
Description
Striated muscle atrophy (GO:0014891) is a biological process in which striated muscle undergoes a decrease in protein content, fiber diameter, force production and fatigue resistance in response to diverse conditions such as starvation, aging and disuse. Striated muscle includes both skeletal muscle, which is responsible for voluntary movement and posture, and cardiac muscle; atrophy in these tissues has profound consequences for mobility, metabolic health and quality of life. The term captures a convergent cellular phenotype that can be triggered by immobilisation, denervation, nutrient deprivation, aging and systemic metabolic disease. At the molecular level, striated muscle atrophy reflects a shift in the balance between protein synthesis and protein degradation, with accelerated proteolysis mediated largely by the ubiquitin-proteasome system and autophagy-lysosomal pathways. The E3 ubiquitin ligases MuRF1 (TRIM63) and MAFbx/atrogin-1 (FBXO32) are among the best-characterized atrophy-related genes and are induced in many catabolic conditions. Mitochondrial dysfunction, altered mitochondrial dynamics and mitophagy also contribute to the loss of muscle mass and function. For researchers, GO:0014891 provides a structured framework to study the mechanisms, biomarkers and therapeutic targets of muscle wasting. It is relevant to a wide range of human conditions, including sarcopenia, cancer cachexia, disuse atrophy after immobilisation, denervation injury, obesity and type-2 diabetes mellitus. This article summarizes the definition, mechanisms, key genes, disease links and experimental approaches for studying striated muscle atrophy, with a focus on CRISPR-based models and functional genomics.
striated muscle atrophy At A Glance
| GO ID | GO:0014891 |
|---|---|
| GO term | striated muscle atrophy |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Decrease in protein content, fiber diameter, force production and fatigue resistance in striated muscle in response to starvation, aging, disuse and other conditions |
| Tissue context | Skeletal muscle and cardiac striated muscle |
| Key molecular players | MuRF1 (TRIM63), MAFbx/atrogin-1 (FBXO32), FoxO transcription factors, ubiquitin-proteasome system, autophagy and mitophagy pathways |
| Major triggers | Starvation, aging, disuse/immobilisation, denervation, metabolic disease and obesity |
| Research relevance | Sarcopenia, cachexia, disuse atrophy, denervation injury and metabolic myopathies |
What Is GO:0014891?
GO:0014891 (striated muscle atrophy) is defined as a process, occurring in striated muscle, that is characterized by a decrease in protein content, fiber diameter, force production and fatigue resistance in response to different conditions such as starvation, aging and disuse. In practical terms, it describes the active loss of muscle mass and function in skeletal or cardiac striated muscle, driven by catabolic signaling and reduced anabolic capacity.
Why Is striated muscle atrophy Important in Cell Biology?
Striated muscle atrophy is a central process in muscle-wasting conditions that affect millions of people worldwide, including sarcopenia, cancer cachexia, disuse atrophy and metabolic disease. Because it involves coordinated changes in protein turnover, mitochondrial function and cell signaling, GO:0014891 provides a mechanistic entry point for identifying therapeutic targets and biomarkers. Understanding this process is also essential for developing interventions that preserve muscle mass and function during aging, immobilisation and chronic disease.
• Sarcopenia: age-related loss of skeletal muscle mass and strength is a major component of striated muscle atrophy and contributes to frailty and disability.
• Disuse atrophy: immobilisation and reduced mechanical loading rapidly induce muscle atrophy, making this a key model for studying the process.
• Denervation injury: loss of motor neuron input drives atrophy and mitochondrial dysfunction in skeletal muscle.
• Metabolic disease: obesity and type-2 diabetes mellitus are associated with skeletal muscle atrophy and dysfunction through myocellular mechanisms.
• Cancer cachexia: systemic inflammation and metabolic reprogramming contribute to muscle wasting in cancer patients.
• Therapeutic target discovery: MuRF1, MAFbx/atrogin-1 and mitochondrial quality control pathways are candidate targets for anti-atrophy interventions.
• Biomarker development: atrophy-related genes and proteins can serve as readouts in preclinical and clinical studies.
• Functional genomics: CRISPR screens and knockout models enable systematic testing of candidate genes in atrophy pathways.
• Aging research: understanding striated muscle atrophy informs interventions to extend healthspan and maintain mobility.
• Cardiac relevance: striated muscle atrophy mechanisms may also inform research on cardiac muscle wasting and heart failure.
What Happens During striated muscle atrophy?
Trigger and catabolic signaling
In simple terms: When muscle is not used, starved, or exposed to stress, it receives signals that tell it to break down protein.
Striated muscle atrophy is initiated by conditions such as starvation, aging, disuse, denervation and metabolic stress, which activate catabolic signaling pathways. These triggers converge on transcriptional programs that increase the expression of atrophy-related genes, including E3 ubiquitin ligases, and suppress anabolic pathways. In denervation models, loss of motor neuron input rapidly induces atrophy and mitochondrial dysfunction.
Protein degradation via ubiquitin-proteasome system
In simple terms: The cell tags muscle proteins with ubiquitin so they can be destroyed by the proteasome.
A hallmark of striated muscle atrophy is increased protein degradation mediated by the ubiquitin-proteasome system. The E3 ubiquitin ligases MuRF1 (TRIM63) and MAFbx/atrogin-1 (FBXO32) are induced in multiple atrophy models and target sarcomeric and other proteins for degradation. Their expression is regulated by FoxO transcription factors and other catabolic signaling pathways.
Autophagy and lysosomal degradation
In simple terms: Cells also recycle damaged components through a self-digestion process called autophagy.
In addition to the ubiquitin-proteasome system, autophagy-lysosomal pathways contribute to muscle protein breakdown during atrophy. Mitochondrial dysfunction and altered mitophagy are increasingly recognized as key mechanisms linking mitochondrial quality control to muscle wasting. Dysregulated mitophagy can exacerbate oxidative stress and accelerate the loss of muscle mass and function.
Mitochondrial dysfunction and dynamics
In simple terms: The energy-producing mitochondria in muscle become damaged and are not cleared properly, which worsens muscle loss.
Mitochondrial dysfunction, impaired mitochondrial dynamics and altered mitophagy are integral to the pathogenesis of skeletal muscle atrophy. Denervation-induced atrophy is associated with mitochondrial dysfunction, mitophagy and apoptosis via the miR-142a-5p/MFN1 axis. Targeting mitochondrial quality control pathways may therefore represent a therapeutic strategy for muscle atrophy.
Loss of force production and fatigue resistance
In simple terms: As muscle fibers shrink and proteins are degraded, the muscle becomes weaker and tires more easily.
The functional consequences of striated muscle atrophy include decreased fiber diameter, reduced force production and diminished fatigue resistance. These changes reflect the loss of contractile proteins and impaired metabolic capacity. In aging and metabolic disease, these functional deficits contribute to reduced mobility and increased risk of falls and disability.
Key Genes Involved in GO:0014891 striated muscle atrophy
The following genes and proteins are central to the regulation and execution of striated muscle atrophy, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TRIM63 (MuRF1) | E3 ubiquitin ligase that targets sarcomeric proteins for degradation during atrophy | Established marker and effector of skeletal muscle atrophy; knockout models are used to study atrophy resistance |
| FBXO32 (MAFbx/atrogin-1) | E3 ubiquitin ligase induced in multiple atrophy models; promotes protein degradation | Key atrophy marker; target for functional studies and therapeutic intervention |
| FOXO1 | Transcription factor that activates atrophy-related genes including MuRF1 and MAFbx | Central regulator of catabolic signaling in muscle atrophy |
| FOXO3 | Transcription factor contributing to atrophy gene expression | Involved in protein degradation and autophagy regulation |
| MFN1 | Mitochondrial fusion protein; its dysregulation is linked to denervation-induced atrophy | Target in studies of mitochondrial dynamics and mitophagy in atrophy |
| MIR142 (miR-142a-5p) | MicroRNA that regulates MFN1 and mitochondrial function during denervation | Potential therapeutic target for denervation-induced atrophy |
| AKT1 | Kinase in the IGF-1/PI3K/Akt pathway that suppresses atrophy signaling | Anabolic signaling node; modulation can counteract atrophy |
| MTOR | Kinase that promotes protein synthesis and inhibits autophagy | Central regulator of muscle mass; target for anabolic interventions |
| ULK1 | Autophagy-related kinase regulated by mTOR | Involved in autophagy induction during atrophy |
| MAP1LC3B (LC3B) | Autophagosome marker | Used to monitor autophagy flux in atrophy models |
| SQSTM1 (p62) | Autophagy receptor and signaling adaptor | Readout for autophagic degradation and stress responses |
| PRKN (Parkin) | E3 ubiquitin ligase involved in mitophagy | Key regulator of mitochondrial quality control in muscle |
| PINK1 | Kinase that recruits Parkin to damaged mitochondria | Mitophagy regulator implicated in muscle atrophy |
| NFKB1 | Transcription factor contributing to inflammatory and catabolic signaling | Links inflammation to muscle atrophy |
| TNF | Pro-inflammatory cytokine that can induce muscle wasting | Modeled in cachexia and inflammatory atrophy studies |
| IL6 | Cytokine involved in systemic inflammation and muscle catabolism | Relevant to cachexia and metabolic disease |
| MYOD1 | Myogenic transcription factor involved in muscle differentiation and regeneration | Used to assess regenerative capacity in atrophy models |
| MSTN (Myostatin) | Negative regulator of muscle growth | Target for increasing muscle mass; knockout models exist |
How Is striated muscle atrophy Regulated?
Striated muscle atrophy is regulated by a network of signaling pathways that control protein synthesis and degradation. The IGF-1/PI3K/Akt pathway promotes protein synthesis and suppresses atrophy gene expression, while FoxO transcription factors activate MuRF1 and MAFbx/atrogin-1 when Akt signaling is reduced. mTOR is a central regulator of protein synthesis and autophagy, and its inhibition or activation can shift the balance between muscle growth and atrophy. Inflammatory cytokines such as TNF and IL-6 can also promote catabolic signaling. Mitochondrial quality control pathways, including PINK1/Parkin-mediated mitophagy, are additional regulatory layers that influence muscle mass and function. Denervation specifically induces miR-142a-5p, which targets MFN1 and contributes to mitochondrial dysfunction and atrophy.
striated muscle atrophy and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TRIM63 (MuRF1) | Skeletal muscle atrophy, sarcopenia, disuse atrophy | Knockout mouse or CRISPR knockout cell model to test atrophy resistance |
| FBXO32 (MAFbx/atrogin-1) | Skeletal muscle atrophy, cachexia | Knockout or knockdown models to assess protein degradation |
| MFN1 | Denervation-induced atrophy, mitochondrial dysfunction | CRISPR knockout or overexpression in muscle cells to study mitochondrial dynamics |
| PINK1 | Mitophagy dysfunction, muscle atrophy | Knockout models to assess mitochondrial quality control |
| PRKN (Parkin) | Mitophagy dysfunction, muscle atrophy | Knockout or point-mutation models to study mitophagy |
Sarcopenia and aging
Age-related skeletal muscle atrophy, or sarcopenia, is a major cause of frailty, disability and loss of independence in older adults. It involves progressive loss of muscle mass and strength, with contributions from altered protein turnover, mitochondrial dysfunction and reduced regenerative capacity. Research on GO:0014891 provides mechanistic insights that can inform interventions to preserve muscle function during aging.
Disuse and immobilisation atrophy
Immobilisation, bed rest and reduced mechanical loading rapidly induce skeletal muscle atrophy in humans. Human studies have provided mechanistic insights into the molecular and cellular changes that occur during immobilisation-induced atrophy, including alterations in protein synthesis and degradation. These models are valuable for testing countermeasures such as exercise, nutrition and pharmacological interventions.
Denervation and neuromuscular disease
Loss of motor neuron input, as occurs in denervation injuries and neuromuscular disorders, drives skeletal muscle atrophy and mitochondrial dysfunction. Denervation-induced atrophy involves miR-142a-5p/MFN1 signaling, mitophagy and apoptosis. Understanding these mechanisms may inform therapeutic strategies for preserving muscle in denervation conditions.
Obesity, type-2 diabetes and metabolic disease
Skeletal muscle atrophy and dysfunction are increasingly recognized in obesity and type-2 diabetes mellitus, with myocellular mechanisms including altered protein turnover, mitochondrial dysfunction and inflammation. These metabolic conditions can exacerbate muscle loss and impair glucose homeostasis. Targeting atrophy pathways may have benefits for both muscle and metabolic health.
From striated muscle atrophy-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TRIM63 protect against disuse atrophy? | TRIM63 knockout mouse or CRISPR knockout muscle cell line |
| Does FBXO32 overexpression induce atrophy in vitro? | FBXO32 overexpression in myotubes |
| Does a point mutation in MFN1 alter mitochondrial dynamics during denervation? | CRISPR point-mutation knock-in in muscle cells |
| Does tagging of PINK1 affect mitophagy flux? | Tagged knock-in of PINK1 in muscle cells |
| Does FOXO1 activation drive atrophy gene expression? | FOXO1 overexpression or constitutive activation model |
| Does mTOR inhibition exacerbate atrophy? | mTOR knockout or point-mutation models |
How to Study the striated muscle atrophy Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify atrophy-related genes and pathways |
| Proteomics | Protein abundance and modifications | Discover E3 ligase substrates and degradation targets |
| Seahorse assay | Mitochondrial respiration | Assess mitochondrial function in atrophy models |
| Mitophagy flux assay | Autophagic degradation of mitochondria | Study PINK1/Parkin-dependent mitophagy |
| Histology | Fiber cross-sectional area and type | Quantify muscle atrophy in tissue sections |
| Immunofluorescence | Protein localization and expression | Visualize MuRF1, MAFbx and sarcomeric proteins |
| Western blot | Protein levels and signaling activation | Measure atrophy markers and pathway activity |
| CRISPR screening | Gene function at scale | Identify novel regulators of muscle atrophy |
Transcriptomics and RNA-seq
RNA sequencing can quantify changes in atrophy-related gene expression, including MuRF1 and MAFbx/atrogin-1, across atrophy models. It is widely used to identify differentially expressed genes and pathways in skeletal muscle during disuse, aging and metabolic disease.
Proteomics and protein turnover assays
Proteomic approaches measure changes in protein abundance and post-translational modifications during atrophy, providing insights into degradation and synthesis rates. These methods can identify substrates of E3 ubiquitin ligases and validate targets in muscle cells.
Mitochondrial function and mitophagy assays
Mitochondrial respiration, membrane potential and mitophagy flux can be assessed using Seahorse analysis, fluorescent reporters and electron microscopy. These assays are essential for studying the mitochondrial contributions to striated muscle atrophy.
Histology and imaging
Muscle fiber cross-sectional area, fiber type and myofibrillar protein content can be quantified by histology and immunofluorescence. Imaging of mitochondrial networks and autophagosomes provides spatial information on atrophy mechanisms.
How CRISPR Can Be Used to Study GO:0014891 striated muscle atrophy
Knockout
CRISPR knockout of atrophy-related genes such as TRIM63, FBXO32, MFN1 or PINK1 can test their causal role in striated muscle atrophy. Knockout cell models and mice are used to assess changes in protein degradation, mitochondrial function and muscle mass.
Point Mutation
Point mutations can be introduced into genes such as MFN1 or PINK1 to dissect domain-specific functions in mitochondrial dynamics and mitophagy during atrophy. These models help distinguish catalytic activity from scaffolding functions.
Knock-in
Knock-in of tags or reporters (e.g., fluorescent tags on LC3B or PINK1) enables real-time monitoring of autophagy and mitophagy in muscle cells. Tagged knock-in models are valuable for imaging and biochemical studies.
Overexpression
Overexpression of atrophy drivers such as FOXO1, FBXO32 or TRIM63 can induce atrophy-like phenotypes in muscle cells and animal models. Overexpression models are used to test whether a candidate gene is sufficient to drive muscle wasting.
How EDITGENE Supports striated muscle atrophy Research
Researchers studying striated muscle atrophy-related genes often need to determine whether a candidate gene is causally involved in the process or merely a biomarker. CRISPR-based models provide a rigorous way to test gene function through knockout, point mutation, knock-in and overexpression approaches.
Contact EDITGENE today to design your custom CRISPR model for striated muscle atrophy research.
Frequently Asked Questions About striated muscle atrophy
What is striated muscle atrophy (GO:0014891)?
Striated muscle atrophy is a biological process characterized by a decrease in protein content, fiber diameter, force production and fatigue resistance in striated muscle in response to conditions such as starvation, aging and disuse.
What genes are involved in striated muscle atrophy?
Key genes include TRIM63 (MuRF1), FBXO32 (MAFbx/atrogin-1), FOXO1, FOXO3, MFN1, PINK1, PRKN and MTOR, among others.
What causes striated muscle atrophy?
Causes include starvation, aging, disuse/immobilisation, denervation, metabolic disease and obesity, all of which activate catabolic signaling and protein degradation.
How is striated muscle atrophy measured?
It is measured by fiber cross-sectional area, protein content, force production and fatigue resistance, as well as molecular markers such as MuRF1 and MAFbx expression.
What is the role of MuRF1 in muscle atrophy?
MuRF1 (TRIM63) is an E3 ubiquitin ligase that targets sarcomeric proteins for degradation and is a established marker and effector of skeletal muscle atrophy.
What is the role of MAFbx/atrogin-1 in muscle atrophy?
MAFbx/atrogin-1 (FBXO32) is an E3 ubiquitin ligase induced in multiple atrophy models and promotes protein degradation.
How does mitochondrial dysfunction contribute to muscle atrophy?
Mitochondrial dysfunction, altered dynamics and impaired mitophagy contribute to oxidative stress and loss of muscle mass and function during atrophy.
What diseases are associated with striated muscle atrophy?
Sarcopenia, cancer cachexia, disuse atrophy, denervation injury, obesity and type-2 diabetes mellitus are associated with striated muscle atrophy.
Can CRISPR be used to study striated muscle atrophy?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models are used to test the causal role of atrophy-related genes.
What are the main signaling pathways in striated muscle atrophy?
The IGF-1/PI3K/Akt pathway, FoxO transcription factors, mTOR signaling, ubiquitin-proteasome system and autophagy-mitophagy pathways are central.
Conclusion
GO:0014891 (striated muscle atrophy) is a fundamental biological process that underlies muscle wasting in aging, disuse, denervation and metabolic disease. Its mechanisms involve coordinated changes in protein degradation, mitochondrial function and cell signaling, with MuRF1 and MAFbx/atrogin-1 as key effectors. Continued research using CRISPR-based models and functional genomics will help identify therapeutic targets and biomarkers for preserving muscle mass and function.
References
- 1. Yin L et al.. 2021. Skeletal muscle atrophy: From mechanisms to treatments.. Pharmacol Res 172:105807 PMID: 34389456
- 2. Deane CS et al.. 2024. Skeletal muscle immobilisation-induced atrophy: mechanistic insights from human studies.. Clin Sci (Lond) 138(12):741-756 PMID: 38895777
- 3. Naruse M et al.. 2023. Human skeletal muscle-specific atrophy with aging: a comprehensive review.. J Appl Physiol (1985) 134(4):900-914 PMID: 36825643
- 4. Bodine SC et al.. 2014. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1.. Am J Physiol Endocrinol Metab 307(6):E469-84 PMID: 25096180
- 5. Jun L et al.. 2023. Prevalence and Mechanisms of Skeletal Muscle Atrophy in Metabolic Conditions.. Int J Mol Sci 24(3) PMID: 36769296
- 6. Castillo ÍMP et al.. 2025. Skeletal muscle atrophy and dysfunction in obesity and type-2 diabetes mellitus: Myocellular mechanisms involved.. Rev Endocr Metab Disord 26(5):815-836 PMID: 40064750
- 7. Yang X et al.. 2020. Denervation drives skeletal muscle atrophy and induces mitochondrial dysfunction, mitophagy and apoptosis via miR-142a-5p/MFN1 axis.. Theranostics 10(3):1415-1432 PMID: 31938072
- 8. Lei Y et al.. 2024. The role of mitochondrial dynamics and mitophagy in skeletal muscle atrophy: from molecular mechanisms to therapeutic insights.. Cell Mol Biol Lett 29(1):59 PMID: 38654156
